Jump to:
Ray Grant advises clients across the global life sciences industry in a wide range of strategic transactions, including early-stage venture capital investments, growth equity investments, PIPEs, joint ventures, and carve-outs. He represents life-sciences focused venture capital and private equity investment funds and biopharmaceutical companies. Ray’s breadth of transactional experience across the life sciences industry, including his secondment with Bain Capital Life Sciences, has positioned him to provide pragmatic, business-oriented advice to clients, leading to long-term and trusted relationships.
Experience
- Bain Capital Life Sciences:
- on the creation of a new biopharmaceutical company focused on developing new therapies for autoimmune diseases. The newly formed company launched with five immunology assets in-licensed from Bristol Myers Squibb and a $300 million financing commitment that was led by Bain Capital.
- in the formation and $400 million Series A financing of Kailera Therapeutics, a clinical-stage biopharmaceutical company developing treatment options for obesity and related conditions, and the worldwide (ex-China) licensing by Kailera of a portfolio of clinical-stage metabolic disease assets from Hengrui Pharmaceuticals.
- in its investment in Cerevel Therapeutics, a biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system.
- as a lead investor in an over $200 million strategic growth transaction centered on Serán Bioscience.
- in its public company investing, including PIPE investments in Annexon, Century Therapeutics, Cidara Therapeutics, Dianthus Therapeutics, Dicerna Pharmaceuticals, Olema Pharmaceuticals, Pharvaris, Savara, Solid Biosciences,Syros Pharmaceuticals,Tango Therapeutics, X4 Pharmaceuticals, and Xilio Therapeutics.
- Perceptive Life Sciences:
- as a lead investor in the $136 million financing of Impulse Dynamics, a global medical device company.
- as a lead investor in the $300 million Series A financing of Kardigan, a heart health company.
- as a lead investor in the $150 million convertible preferred stock PIPE financing of Rhythm Pharmaceuticals, a commercial-stage biopharmaceutical company.
- in a strategic partnership with Lexeo Therapeutics and venBio Partners to develop novel RNA-based therapeutics for genetic cardiac diseases through a new entity backed by up to $40 million in private equity financing from Perceptive and venBio.
- Sanofi:
- in a strategic investment up to $25 million in Adagene and the exercise of its option for a third SAFEbody discovery program.
- in a strategic investment in SAB BIO as part of its $175 million private placement, alongside other investors.
- in a strategic investment of $25 million in Immuneering.
- Patient Square in its participation in the $300 million financing of GondolaBio, a development stage therapeutics company spun out of BridgeBio.
- RTW Investments in the formation of Prolium Bioscience, its initial Series A financing, and its foundational license agreement with InnoCare Pharma and KeyMed Biosciences.
- Redmile as a lead investor in the $155 million Series B financing of Abcuro, a clinical-stage biotechnology company.
- Tissento Therapeutics, a clinical-stage biopharmaceutical company, in its formation and Series A financing.
- A children’s hospital on the spin-out of its therapeutic research division into a focused biotechnology company.
- Tenacia Biotechnology Company, a Bain Capital portfolio company, in an exclusive collaboration and license agreement with Praxis Precision Medicines and its related equity investment in Praxis.
- Novalis LifeSciences as a lead investor in convertible preferred stock PIPE financing of Telesis Bio, a provider of molecular solutions for synthetic biology applications.
- J. Wood Capital Advisors LLC as private placement agent to Repligen Corp. in a $600 million convertible senior notes financing.
- The underwriters in the:
- $315 million initial public offering of Bicara Therapeutics.
- $1.7 billion initial public offering of Elanco Animal Health.
- $56 million initial public offering of CRISPR Therapeutics.
- $69 million initial public offering of Unum Therapeutics.
- $95 million initial public offering of AveXis.